

EXPRESS MAIL NO.: EV 531 712 866 US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application of:	Ensoli	Confirmation No.:	To Be Assigned
Application No.:	To Be Assigned (National Stage of PCT/EP02/04303, filed April 18, 2002)	Art Unit:	To Be Assigned
Filed:	On even date herewith	Examiner:	To Be Assigned
For:	USE OF INHIBITORS OF THE PROTEASE OF THE HUMAN IMMUNODEFICIENCY VIRUS (HIV) TO BLOCK CELL MIGRATION AND/OR INVASION, TISSUE INFILTRATION AND OEDEMA FOR THE THERAPY OF DISEASES ASSOCIATED THEREWITH	Attorney Docket No.:	11340-007-999

**INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. § 1.56 AND § 1.97**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure imposed by 37 C.F.R. § 1.56 to inform the U.S. Patent and Trademark Office of all references coming to the attention of each individual associated with the filing and prosecution of the subject application which are or may be material to the patentability of any claim of the application, Attorneys for Applicant respectfully direct the Examiner's attention to references A01, B01-B02 and C01-C05 listed on the attached revised PTO/SB/08 Form entitled "List of References Cited by Applicants." Pursuant to 37 C.F.R. § 1.98(a)(2)(i), copies of the cited U.S. patents and U.S. patent application publications (*i.e.*, reference A01) are not submitted herewith. A copy of references B01-B02 and C01-C05 is submitted herewith.


Identification of the listed references is not to be construed as an admission of Applicant or Attorneys for Applicant that such references are available as "prior art" against the subject application.

Applicant respectfully requests that the Examiner review the listed references and that the references be made of record in the file history of the application.

Pursuant to 37 C.F.R. § 1.97(b), since this Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits, it is believed that no fee is due in connection herewith. However, should the Patent and Trademark Office determine otherwise, please charge the required fee to Jones Day Deposit Account No. 50-3013.

Respectfully submitted,

Date: September 15, 2005

 32,605  
Adriane M. Antler (Reg. No.)  
**JONES DAY**  
222 East 41<sup>st</sup> Street  
New York, New York 10017  
(212) 326-3939

## LIST OF REFERENCES CITED BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.

11340-007-999

APPLICATION NO.

To Be Assigned

(National Stage of  
PCT/EP02/04303, filed  
April 18, 2002)

APPLICANT

Ensoli

FILING DATE

On Even Date Herewith

GROUP

To Be Assigned

## U.S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	A01	6,506,555	01/14/03	Andre et al.			

## FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	B01	WO 99/63998	12/16/99	PCT (with English abstract)				
	B02	WO 00/33654	06/15/00	PCT				

## OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	C01	Andre et al. An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses. Proc Natl Acad Sci U S A. 1998 Oct 27;95(22):13120-4.
	C02	Berthelot et al. Dramatic cutaneous psoriasis improvement in a patient with the human immunodeficiency virus treated with 2',3'-dideoxy,3'-thyacytidine [correction of 2',3'-dideoxycytidine] and ritonavir. Arch Dermatol. 1997 Apr;133(4):531.
	C03	Conant et al. Reduction of Kaposi's sarcoma lesions following treatment of AIDS with ritonavir. AIDS. 1997 Aug;11(10):1300-1.
	C04	Sgadari et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med. 2002 Mar;8(3):225-32.
	C05	International Search Report for International Application No. PCT/EP02/04303.

EXAMINER

DATE CONSIDERED

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.